Transforming Care for Cancer Patients

2019 ANNUAL REPORT HIGHLIGHTS
At NorthShore University HealthSystem (NorthShore) Kellogg Cancer Center, we are dedicated to improving patient outcomes. We come together in teams of specially trained physicians, nurses and other healthcare professionals using the most advanced technology and sophisticated personalized medicine to provide the best possible care to individual patients.

From the rapidly evolving world of immunotherapy—which we are prioritizing with a comprehensive new program—to our nationally recognized molecular pathology and diagnostics laboratory, to a wide array of clinical trials and sophisticated surgical techniques, our patients have access to the latest and most effective therapies.

We are also committed to providing a full range of supportive services, like our unique tobacco cessation program and newly available cooling caps to reduce hair loss for patients undergoing chemotherapy.

Our patients also benefit from our academic affiliation with the University of Chicago Pritzker School of Medicine. In addition to our shared medical training programs, patients benefit from our shared clinical and research programs and our combined expertise.

NorthShore is certified by the American Society of Clinical Oncology (ASCO) Quality Oncology Practice Initiative (QOPI) as a premier medical provider for practicing the highest standards of quality cancer care. NorthShore is recognized in *U.S. News & World Report*’s Best Hospitals Survey as the #3 Hospital in Chicagoland and the state of Illinois.

We are grateful to our philanthropic supporters and honored by the trust of patients who come to us for care. The highlights described in this report reflect our collective commitment to innovation and outstanding care.

Bruce Brockstein, MD
Medical Director, NorthShore Kellogg Cancer Center, Head, Division of Hematology/Oncology, Kellogg-Scanlon Chair of Oncology

David J. Winchester, MD
Chairman, NorthShore Cancer Committee, Associate Director for Surgical Specialties, NorthShore Kellogg Cancer Center Board of Directors, David P. Winchester, MD, Chair of Surgical Oncology

**Progress in Lung Cancer Care**

**Innovative Research**

NorthShore was one of 18 institutions participating in an important multicenter trial for metastatic non-small cell lung cancer patients. The study aims to determine the best sequencing of chemotherapy and immunotherapy for optimal outcomes. One hundred patients took part in the randomized trial led nationally by NorthShore principal investigator oncologist Thomas Hensing, MD, MS, who presented results at the American Society of Clinical Oncology (ASCO) international conference. Patient outcomes are still being monitored, although initial data revealed that a specific subgroup of patients may benefit the most from chemotherapy first, followed by immunotherapy, said Dr. Hensing, who hopes to continue to build on this study with further research.

**Screening Saves Lives**

Another large, randomized trial—the Nelson Study—confirmed that appropriately deployed lung cancer screening saves lives. Presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, the Nelson Study showed that annual lung cancer screening with low-dose computed tomography (CT) in high-risk patients reduced lung cancer deaths by 26% in men and up to 61% in women. Kellogg Cancer Center was an early adopter and promoter of CT lung screening for smokers and former smokers at higher risk of developing lung cancer.

According to the American Cancer Society prediction of 160,000 lung cancer deaths in the United States, screening could save up to 65,000 American lives each year. Lung cancer kills more people annually than breast, colon and prostate cancers combined.

**Increased Survival Rates**

One of NorthShore’s key strengths in caring for lung cancer patients is our advanced molecular testing. The ability to do this testing on-site with rapid turnaround is critical to developing personalized treatment plans that offer patients the best care options as quickly as possible. Kellogg Cancer Center team has been a leader in using tumor biology to personalize care and will continue to expand these efforts, which have helped improve survival rates and quality of life.

For more information, visit northshore.org/cancer or call (847) 570-2112
Lifesaving Collaborative Care

Four years ago, Aislinn Bujewski had a small lump removed from her thigh. A healthy, active 46-year-old mother of three, Bujewski assumed it was a cyst and barely gave it a second thought. When pathology results revealed that it was actually metastatic melanoma, Bujewski was in total shock. “It was one of those surreal moments when it felt like time stopped,” she said.

A client/friend of Bujewski’s connected her to NorthShore oncologist and Kellogg-Scanlon Chair of Oncology Bruce Brockstein, MD, a specialist with expertise in melanoma, who quickly worked to develop a treatment plan. A PET scan revealed the cancer had already spread to her liver and lymph nodes.

“I told Dr. Brockstein, ‘Just come up with a game plan.’ I’m very stubborn, and I refused to let this win,” said Bujewski, who is a professional horse trainer and avid runner.

Dr. Brockstein started her on an advanced immunotherapy treatment—nivolumab infusions she received every other week for 18 months. “The timing of this was kind of a miracle,” said Dr. Brockstein. “Even five years ago, before we had this immunotherapy, she would have likely died in four to six months.”

“As scared as I was after the initial diagnosis, within five minutes of meeting Dr. Brockstein, I was thinking ‘This is going to be OK.’ He was going to be in charge of it, and I felt very calm,” said Bujewski. “And the whole team at Kellogg Cancer Center was great. As much as I dreaded the process, everyone from the nurses and techs to the receptionists all made it so much easier.”

Although the cancer disappeared from the lymph nodes, the large tumor in the liver remained unchanged in size. Following multidisciplinary consultation, her care team decided that in addition to the immunotherapy, Bujewski should have a major liver resection with Stanton and Margaret Rogers Palmer Chair of Surgery Mark S. Talamonti, MD, who removed the entire right lobe of her liver in an advanced, minimally-invasive procedure.

“This was a remarkable case. We told her we were working with evolving technology, and she had the confidence to go forward,” recalled Dr. Talamonti. “She was in such great shape, and there was no evidence of cancer on the healthy section of her liver. She met the highly selective criteria for this pioneering approach.” Most, but not the entire removed liver tumor was dead tissue from the immunotherapy.

Bujewski has now been cancer-free for close to four years, and her prognosis is very good, according to Dr. Brockstein.

“I’ve been very lucky. I never stopped working, and I never stopped working out. I was grateful to keep up my running regimen,” said Bujewski, who completed her first marathon in 2018 and has two more on the calendar in 2019.

“This kind of treatment obviously changes your life, but it taught me a lot. It made me realize you’re as strong as you need to be,” she added. “If I hadn’t come to NorthShore for treatment, I’m not sure I’d still be here and able to watch my kids grow up.”

For more information, visit northshore.org/cancer or call (847) 570-2112
Cancer Center has been at the forefront of the fight against cancer, and Kellogg Cancer Center now comes with fewer side effects. Notably, significant improvements in cancer outcomes have been achieved.

### Immunotherapy

**Immune Checkpoint Inhibitors**

Immune checkpoint inhibitors are currently the most widely used and successful type of immunotherapy. These drugs “release the brakes” that keep T cells of the immune system from killing cancer cells. Rather than targeting the tumor directly, these drugs enable the patient’s own immune system to target the tumor directly, these drugs enable the patient’s own immune system to spot cancer cells and destroy them. Immune checkpoint inhibitors have now been shown to have a clear benefit for 13 different cancers, and that number will continue to grow with ongoing research.

At Kellogg Cancer Center, we have kept pace with national trends in both clinical use and research on these lifesaving drugs. In fiscal year 2018, a total of 300 patients received immunotherapy. In 2019, 475 are projected and by 2020, more than 500 (or about 30%) of our medically treated cancer patients will receive immunotherapy.

We are now launching a formal, coordinated Immunotherapy Program at Kellogg Cancer Center to take this work to the next level in both clinical care and clinical and translational research. The dedicated program will build on many existing strengths, including exceptional clinical care and laboratory services.

While we participate in numerous clinical trials involving immunotherapy, the new program will expand our research efforts in clinical and translational research, ensuring that patients have access to the latest advancements. Already our Kellogg Cancer Center team has published several papers and 11 abstracts related to immunotherapy clinical and translational research. The new program will also expand existing partnerships with our collaborators at University of Chicago and other distinguished institutions.

### Molecular Diagnostics

**Drives Personalized Medicine**

NorthShore’s Pathology and Laboratory Medicine Department offers an impressive array of services, including our Molecular Diagnostics Laboratory, an early leader in genomic testing and analysis. We continue to provide next-generation sequencing to analyze tumors at a genetic level and can even analyze micro-needle aspiration samples, all with a rapid turnaround. Results from these high-level tests performed on-site with very rapid turnaround times routinely form the basis for selection of optimal personalized therapy for patients with lung cancer, melanoma, colon and other cancers.

Led by Linda Sabatini, PhD, the Molecular Diagnostics Laboratory is launching new next-generation panels for hematologic malignancies, offering these patients the most advanced DNA-based techniques to deliver personalized care. Clonality testing, launched in 2016, helps in the diagnosis of leukemias and lymphomas.

This year, we will expand our current 50-gene panel test to a 400-plus gene panel test that will include tumor mutational burden, information that can help guide immunotherapy treatment. The analysis of tissue from tumor metastases can identify biomarkers of aggressive behavior, and potential therapeutic targets, potential mechanisms of resistance to therapy. The analysis of circulating tumor DNA (shed into the patient’s bloodstream) can also aid in the identification of biomarkers of resistance and/or response to targeted therapies. The expanded capability will provide a broader view of the genetic alterations in a patient’s tumor.

The Molecular Diagnostics Laboratory is an integral component of NorthShore’s pharmacogenomics program. It is expanding efforts to work with cancer patients and alleviate the need for trial and error with medications for pain management and anxiety/depression.
**Beating the Odds**

Doris Murillo was 52 years old and a self-described workaholic who never took a day off when she had a feeling that something was not right and asked her oldest son to take her to the hospital.

“I was so tired, my chest hurt, my back hurt and I couldn’t stop coughing,” said Murillo. It didn’t take long to learn that she had lung cancer. “I smoked, my friends and family smoked, but still it was a shock. I didn’t think it would happen that soon,” she recalled.

Murillo was referred to Kellogg Cancer Center oncologist Thomas Hensing, MD, who has treated the now 57-year-old mother of four and grandmother of six with advanced immunotherapy, giving her a new lease on life and time to spend with her family.

“He explained everything in a very detailed way, and he didn’t sugarcoat anything,” said Murillo, who struggled with her initial chemotherapy and relapsed early in the course of treatment. Dr. Hensing then put Murillo on an immunotherapy medication, which although not as commonly used for small cell lung cancer like hers, has been very successful in her case. “She’s in remission now, and it’s very gratifying to be able to offer her this treatment,” said Dr. Hensing.

Murillo quit smoking after her diagnosis and hopes everyone in her family will follow. She is grateful for the care she received and for the compassionate caregivers, including Advanced Practice Nurse JoAnn Eriksson and all Kellogg Cancer Center nurses who have been part of her care team.

“Sometimes I get out of breath, but generally I feel OK, and I’m very happy that I’m still here. I thank God for every day, and I’m very thankful for Dr. Hensing. He’s been an awesome doctor and a really good person,” said Murillo. “I refuse to give up. I don’t feel like it’s my time yet.”

**Leader in Oncoplastics**

Katherine Kopkash, MD, FACS, Director of Oncoplastic Breast Surgery at NorthShore, led a novel study looking at ergonomics for breast surgeons, and presented the results at the national meeting of the American Society of Breast Surgeons in May to an enthusiastic audience. The research will also be published in the *Annals of Surgical Oncology*.

Breast surgeons like Dr. Kopkash are doing more and more risk-reducing surgeries as awareness around genetic testing and high-risk patients continues to build. Nipple-sparing mastectomies, which are often favored by patients, are long and complicated procedures that can be physically taxing for surgeons, whose bodies are often contorted for hours.

Dr. Kopkash and three of her colleagues wore EMGs (electromyographs) during surgery to analyze muscle use and then participated in questionnaires after completing procedures. As a follow-up study, Dr. Kopkash used the initial data to develop an exercise program, working with a kinesiologist/personal trainer to identify exercises to strengthen the muscles most used during surgery. She also developed an operating room protocol that included specific table positions to help ease muscle strain for surgeons. This study was unique in its consideration of the long-term health and work capacity of the surgeon, recognizing that maximizing the surgeon’s comfort maximizes the patient’s opportunity for optimal outcomes.

A national leader in the growing field, Dr. Kopkash sits on the Oncoplastics Committee for the American Society of Breast Surgeons and taught its quickly sold-out oncoplastics course hosted at NorthShore. She also held an oncoplastics lab for residents who were able to practice oncoplastic techniques on breast surgical simulators called Mastotrainers. This is the only oncoplastic resident training program in the country. The simulation training was featured in a video presentation at a recent American Society of Breast Surgeons meeting.

**Crucial Clinical Trials**

Patients at Kellogg Cancer Center have access to a broad array of clinical trials and potentially lifesaving new treatments. Research is a critical part of our commitment to providing the best possible care for patients today and driving improvements in treatment.

Surgical Oncology Division Head Katharine Yao, MD, is the site principal investigator of the Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Study, a trial that is studying treatment options for low-risk ductal carcinoma in-situ (DCIS). NorthShore is one of 83 national sites participating in the study, which may prove groundbreaking in how DCIS cancer patients are treated.

The randomized trial assigns patients to one of two groups receiving either: (1) breast surgery with the option of radiation and/or endocrine therapy, and (2) active surveillance or close monitoring with the option of endocrine therapy. The study is sponsored by Alliance Foundation Trials.

For a complete list of active trials, visit: northshore.org/Kellogg-cancer-center/clinical-trials

For more information, visit northshore.org/cancer or call (847) 570-2112
Community Partners

Kellogg Cancer Center has a number of key partnerships and collaborations.

- Social workers, nutritionists and financial advocates are connected to internal collaborators and external organizations where we can refer patients for additional resources.
- Our outreach coordinator fosters key partnerships with the Cancer Wellness Center, Leukemia & Lymphoma Society, the American Cancer Society (ACS) and others.
- We host monthly Imerman Angels socials and partner with ACS for virtual programs and more.

Fueling the Fight

Registered dietitians with specialized oncology expertise see patients at all three Kellogg Cancer Centers, as nutrition is an important part of the treatment and healing process. Fueling the Fight: Recipes with Cancer-Fighting Benefits, an online cookbook with some of our dietitians’ favorite recipes, was released this year.

A well-balanced meal with cancer-fighting benefits, including phytochemicals, does not have to be difficult to create or boring to eat. Phytochemicals are protective compounds found in the pigments of plants that have been shown to stimulate the immune system, slow the growth rate of cancer cells and prevent DNA damage that can lead to cancer. A diet consisting of an abundance of plant foods—including a variety of vegetables, legumes, herbs, spices and fruits—is the first step to eating more phytochemicals.

The recipes in Fueling the Fight can help boost the cancer-fighting properties of individual and family meal plans. Kellogg Cancer Center nurses led the initiative to provide support for patients experiencing hair loss during chemotherapy.

One of many cancer patients’ greatest fears is losing their hair. Kellogg Cancer Center now offers patients undergoing specific types of chemotherapy treatments the option of new scalp cooling caps to reduce hair loss. The cooling caps are not appropriate for all patients but offer a good option for those receiving certain chemotherapy drugs and who are very committed to minimizing hair loss.

The Paxman caps are worn for 30 minutes before treatment, through chemotherapy and up to an additional 90 minutes after the treatment. The cap reduces the temperature of the scalp, which reduces the blood flow to hair follicles to prevent or minimize hair loss. Kellogg Cancer Center nurse Bonnie Ryszka, RN, spearheaded the effort to bring the cooling cap program to NorthShore patients.

Benefit Concert Supports Integrative Medicine

Close to 1,000 people attended a benefit concert for NorthShore’s Integrative Medicine Program on a snowy January evening, raising funds to provide integrative medicine therapies including acupuncture, bodywork and integrative medicine physician consultations for Kellogg Cancer Center patients.

Sons of the Silent Age performed David Bowie’s “Scary Monsters” and other Bowie hits at the Metro in Chicago. Actor Michael Shannon joined the band as Lou Reed.
Cancer screening activities are vital work for quality cancer programs. They are designed to decrease the number of patients diagnosed with a specific cancer at a late stage and increase the likelihood of survival.

Breast cancer is the second leading cause of cancer-related death among women. Screening mammography is associated with a 30% to 40% reduction in breast cancer mortality among women ages 40 to 74. Early detection through screening is key to improved survival. The overall prognosis is directly linked to the stage of the disease at diagnosis, and timely screening detects breast cancer at earlier stages when the disease is more treatable and even curable.

To address screening needs and access to screening for the underserved, NorthShore partnered with the Lake County Health Department (LCHD) and Community Health Center, located in Waukegan, and offered 200 complimentary mammograms. The screenings were funded by the Myra Rubenstein Weis (MRW) Leadership Board of NorthShore.

Lake County towns—particularly Highwood, North Chicago, Round Lake, Waukegan and Zion—were identified by NorthShore’s Community Health Needs Assessment as geographic areas of greatest need. Also noted was a higher incidence of breast cancer in Lake County (136.5 per 100,000 compared to 127.4 per 100,000 in Illinois and 122.7 per 100,000 in the United States).

Carol Rosenberg, MD, Director of Preventive Health Initiatives at NorthShore, Director of the MRW LIFE Cancer Survivorship Program, and a member of the cancer committee, is studying the results of complimentary screenings offered to those in the community who are cared for by the Lake County North Shore Health Center in Highland Park.

"Importantly—although about half of those screened were found to have a normal mammogram and were advised to receive normal interval follow-up—a significant number of women were also found to have abnormalities, which were scrutinized intensively by our trained radiologists and deemed benign. These patients were also advised to receive normal interval follow-up," said Dr. Rosenberg.

A small number of patients had diagnostic findings, which were indeterminate or suspicious for malignancy and given appropriate follow-up recommendations (see chart to the right). Additional significance of the data implies that mammography itself is only one aspect of screening underserved populations. “Imaging in conjunction with follow-up comparisons, additional imaging and feedback to patients and their primary care physicians is the type of complete, multistep quality process with lifesaving value that we were able to provide with this project,” she added.
Active Clinical Trials

NorthShore patients have access to a broad array of clinical trials and potentially lifesaving new treatments.

For a complete list of active trials, visit northshore.org/kellogg-cancer-center/clinical-trials.

Brain Tumors
- A071101 Phase II randomized trial comparing the efficacy of heat shock protein-90 i.v. vaccine with placebo in the treatment of recurrent glioblastoma multiforme.
- A221101 Phase III randomized and controlled study of placebo to assess the efficacy and safety of intratumoral administration of interferon alpha-2b in patients with glioblastoma multiforme.
- Tocagen/Tg 511-15-01 A Phase II/III randomized, open-label study of Toca 511, a replicative vector, combined with Toca FC versus standard of care in subjects undergoing planned resection for recurrent glioblastoma or anaplastic astrocytoma.

ICT 107 STING (Study of Immunotherapy in Newly Diagnosed Glioblastoma) A Phase III randomized, double-blind, controlled study of ICT 107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concurrent TMZ chemoradiation.

A071102 A Phase II/III trial of veliparib or placebo in combination with adjuvant temozolomide in newly diagnosed glioblastoma with MGMT promoter hypermethylation.

AbbVie/M13-811 A randomized, placebo-controlled Phase Ib/III study of ABT-414 with concurrent chemoradiation and adjuvant temozolomide in subjects with newly diagnosed glioblastoma multiforme (GBM) with epidermal growth factor receptor (EGFR) amplification (Intellience 1).

BCX110-05 Open-label, active comparator (feasibility study) treatment protocol, nirosporinhibor (BCX-110).

AbbVie Preappraisal Access Preappraisal access of ABT-414 for treatment of glioblastoma multiforme (GBM).

Breast Cancer

EA221405 Pregnancy outcome and safety of interrupting therapy for women with endocrine responsive breast cancer (POSITIVE).

EA1131 Randomized Phase III postoperative trial of platinum-based chemotherapy versus observation in patients with residual triple-negative basa-lik breast cancer following neoadjuvant chemotherapy.

NSABP B-51 A randomized Phase III clinical trial evaluating postmastectomy chest wall and regional nodes before neoadjuvant chemotherapy who convert to pathology-negative axillary nodes after neoadjuvant chemotherapy.

A0011401 Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer.

A0011502 A randomized Phase III double-blind placebo-controlled trial of aspirin as adjuvant therapy for node-negative, HER2-negative breast cancer: The ABC trial.

UC16-0403 A randomized, placebo-controlled, double-blind, Phase II trial of nanoparticle albumin-bound paclitaxel (nab-paclitaxel), Abraxane with or without mitobrone for advanced, glucocorticoid receptor-positive, triple-negative breast cancer.

Gastrointestinal Cancer

NRG-GI004/SWOG-S1610 Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of immunotherapy with or without fluoropyrimidine chemotherapy in patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer.

EA2165: A Randomized Phase II Study of Nirvumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer.

A021502 A Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair.

Genitourinary Cancer

Janssen 64091742PCR2001 A Phase II Study and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies.

AFT-19 A Phase III Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer.

PCGTC-c16-168 A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects.

EA1613 Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease Following Docetaxel: The CHARTED 2 Trial.

Gynecologic Cancer

GGG0238 Randomized trial of pelvic irradiation with or without concurrent weekly cisplatin in patients with pelvic-only recurrence of carcinoma of the uterine corpus.

NRG-GY005 A randomized Phase II/III study of the combination of cediranib and olaparib compared to cediranib or olaparib alone, or standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube or primary peritoneal cancer.

AFT-6026 A randomized Phase II trial of paclitaxel and carboplatin versus bevacizumab, etoposide and cisplatin for newly diagnosed advanced-stage and recurrent cheemo-naive stage sex cord-stromal tumors of the ovary.

UC13-1235 Randomized, placebo-controlled Phase II trial of metformin in conjunction with chemotherapy following metformin maintenance chemotherapy in advanced-stage ovarian, fallopian tube and primary peritoneal cancer.

Pilot Study Pilot study of the impact of early palliative care on quality of life in recurrent ovarian, fallopian tube and primary peritoneal cancer.

AGCT1153 A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin Versus Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.

NRG-GY009 A randomized Phase III/IV study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND 134427) Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer.

GGG-3026 A Phase II Trial of Rubicicil (LEO011) Plus Letrozole in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum.

Head and Neck Cancers

HNC Tissue bank tissue/body fluid procurement and clinical data collection for patients with malignancies of the head and neck area and/or premalignant changes.

EA312 Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing.

Merck 3475-689 A Phase II Study of Pembrolizumab in Stage III-IVA Rectosigmoid, Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC).

Enzymech EC-18-202 A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EC-18 in Altering the Severity and Course of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation Therapy for Carcinoma of the Mouth, Oropharynx, Hypopharynx and Nasopharynx.

Hematology

UC14-0899 Phase II randomized trial of continuation of post-transplant maintenance with single-agent lenalidomide versus consolidation/maintenance with ixazomib-lenalidomide-dexamethasone in patients with residual myeloma.

Connect MDS AML The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry.

EA191 Phase III randomized trial of blinatumomab for newly diagnosed B-Cell-negative B lineage acute lymphoblastic leukemia in adults.

CBIMTR Research database for hematopoetic cell transplantation, other cellular therapies and marrow toxic injuries.

UC13-1406 Prospective, Multi-Center Phase III Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas.

EA111 A randomized Phase III trial of Bortezomib, Lenalidomide and Dexamethasone (VRD) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE).

A061202 A Phase III trial of Olaparib, Dexamethasone and Ixazomib for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitors.

TG Therapeutics T8R-205 A Phase IIb Randomized Study to Assess the Efficacy and Safety of the Combination of Ubilutuzumab + TGR-1202 with or without Bendamustine and TGR-1202 Alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma.

A041501 A randomized Phase III trial to evaluate the efficacy of the combination of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody to Frontline Therapy in Young Adults (ages 18-39) with Newly Diagnosed Precursor B-Cell ALL.

UC16-1138 Open-label, single-arm, Phase 2 Study of Initial Treatment with Eloxutuzumab, Carfilzomib (Kyprolis), Lenalidomide (Revlimid) and Low Dose Dexamethasone (E-KRD) in Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy.

A041702 A randomized Phase III study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (> 70 years of age) with Chronic Lymphocytic Leukemia (CLL).

EA6116 A randomized Phase III study of the Addition of Venetoclax to Ibrutinib to Obinutuzumab versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL).

Lung Cancer

Merck 3475-789 A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy with or without Pembrolizumab (MK-3475) in TKI-Resistance EGFR Mutated Patients in Metastatic Non-Squamous, Non-Small Cell Lung Cancer (NSCLC) Participants (KEYNOTE 789).

LungMAP A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer.

Merck 3475-799 A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination with Platinum Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) Patients (KEYNOTE 799).

S1900A A Phase II Study of Rucaparib in Patients with Germline or Ligase High And/or Definitive BRCA 1 / 2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-study).

S1800A A Phase II Study of Ramucirumab Plus MK3475 (Pembrolizumab) versus Standard of Care for Patients with Previously Treated Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study).

EA5163/S1709 INSIGNA A Randomized, Phase III Study of Firstline Immunotherapy Alone or In Combination with Chemotherapy Induction/Maintenance or Post-progression in Advanced, Non-squamous, Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis.
Incidence of Cancer 2018

In 2018, 4,258 new cancer cases were accessioned into the NorthShore University HealthSystem (NorthShore) Cancer Registry. Of those 4,059 cases (95%) were analytic. By definition, analytic cases are those patients newly diagnosed with malignant neoplasm and/or who have received all or part of their first course of treatment at one of our hospitals. The remaining 199 cases (5%) were non-analytic. Non-analytic cases are patients initially diagnosed and treated at another facility who now are receiving treatment for progression or recurrence of their disease at NorthShore. Details by site are provided in Table 1.

Class of Case 2018

Class of Case divides cases into two groups, analytic cases (Class 00-22) and non-analytic cases (Class 30-49).

Class 00-14, which account for 3,486 cases, were those malignancies diagnosed at one of our four hospitals or in an office of our medical group. Once diagnosed with cancer, 3,275 (94%) of our patients remained at NorthShore for their treatment. Class 20-22, totaling 573 cases, were diagnosed elsewhere and referred here for treatment. Class 30-49, a total of 199 cases, were diagnosed and treated elsewhere and referred here for treatment of a recurrence or progression of disease.

Overall Top 10 Sites 2018

The top 10 cancers seen at NorthShore are breast (830), prostate (472), lung and bronchus (359), skin (304), lymphoma (179), bladder (176), central nervous system (177), colon (167), corpus uteri (164) and thyroid (135). These top 10 sites represent 70% of all cancers seen at NorthShore.

Among women, breast cancer continues to be our top site representing 20% of the total cases seen at NorthShore. The next most frequent cancers seen in women were lung, corpus uteri, skin and central nervous system.

Among men, prostate cancer continues to be our top site representing 11% of the total cases seen at NorthShore. The next most frequent cancers seen in men were skin, lung, bladder and lymphoma.

### Table 1: Incidence of Cancer—2018 Data Summary

<table>
<thead>
<tr>
<th>Primary Site</th>
<th>Analytic</th>
<th>Non-Analytic</th>
<th>Total</th>
<th>Percentage</th>
</tr>
</thead>
<tbody>
<tr>
<td>ORAL CAVITY &amp; PHARYNX</td>
<td>86</td>
<td>4</td>
<td>90</td>
<td>2.1</td>
</tr>
<tr>
<td>Lip</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0.0</td>
</tr>
<tr>
<td>Tongue</td>
<td>31</td>
<td>3</td>
<td>34</td>
<td>0.8</td>
</tr>
<tr>
<td>Salivary Glands</td>
<td>13</td>
<td>0</td>
<td>13</td>
<td>0.3</td>
</tr>
<tr>
<td>Floor of Mouth</td>
<td>3</td>
<td>1</td>
<td>4</td>
<td>0.1</td>
</tr>
<tr>
<td>Gum &amp; Other Mouth</td>
<td>13</td>
<td>0</td>
<td>13</td>
<td>0.3</td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0.0</td>
</tr>
<tr>
<td>Tonsil</td>
<td>12</td>
<td>0</td>
<td>12</td>
<td>0.3</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>6</td>
<td>0</td>
<td>6</td>
<td>0.1</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>5</td>
<td>0</td>
<td>5</td>
<td>0.1</td>
</tr>
<tr>
<td>Other Oral Cavity &amp; Pharynx</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0.0</td>
</tr>
<tr>
<td>DIGESTIVE SYSTEM</td>
<td>559</td>
<td>19</td>
<td>578</td>
<td>13.6</td>
</tr>
<tr>
<td>Esophagus</td>
<td>30</td>
<td>1</td>
<td>31</td>
<td>0.7</td>
</tr>
<tr>
<td>Stomach</td>
<td>55</td>
<td>5</td>
<td>60</td>
<td>1.4</td>
</tr>
<tr>
<td>Small Intestine</td>
<td>15</td>
<td>1</td>
<td>16</td>
<td>0.4</td>
</tr>
<tr>
<td>Colon Excluding Rectum</td>
<td>165</td>
<td>2</td>
<td>167</td>
<td>3.9</td>
</tr>
<tr>
<td>Rectum &amp; Rectosigmoid</td>
<td>69</td>
<td>2</td>
<td>71</td>
<td>1.7</td>
</tr>
<tr>
<td>Anus, Anal Canal &amp; Anorectum</td>
<td>14</td>
<td>3</td>
<td>17</td>
<td>0.4</td>
</tr>
<tr>
<td>Liver &amp; Intrahepatic Bile Duct</td>
<td>43</td>
<td>2</td>
<td>45</td>
<td>1.1</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>14</td>
<td>0</td>
<td>14</td>
<td>0.3</td>
</tr>
<tr>
<td>Other Biliary</td>
<td>20</td>
<td>0</td>
<td>20</td>
<td>0.5</td>
</tr>
<tr>
<td>Pancreas</td>
<td>123</td>
<td>3</td>
<td>126</td>
<td>3.0</td>
</tr>
<tr>
<td>Retropertioneum</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0.0</td>
</tr>
<tr>
<td>Peritoneum, Omentum &amp; Mesentery</td>
<td>4</td>
<td>0</td>
<td>4</td>
<td>0.1</td>
</tr>
<tr>
<td>Other Digestive Organs</td>
<td>6</td>
<td>0</td>
<td>6</td>
<td>0.1</td>
</tr>
<tr>
<td>RESPIRATORY SYSTEM</td>
<td>379</td>
<td>8</td>
<td>387</td>
<td>9.1</td>
</tr>
<tr>
<td>Nose, Nasal Cavity &amp; Middle Ear</td>
<td>3</td>
<td>1</td>
<td>4</td>
<td>0.1</td>
</tr>
<tr>
<td>Larynx</td>
<td>22</td>
<td>1</td>
<td>23</td>
<td>0.5</td>
</tr>
<tr>
<td>Lung &amp; Bronchus</td>
<td>353</td>
<td>6</td>
<td>359</td>
<td>8.4</td>
</tr>
<tr>
<td>Trachea, Mediastinum &amp; Other Respiratory Organs</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0.0</td>
</tr>
<tr>
<td>BONES &amp; JOINTS</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td>0.1</td>
</tr>
<tr>
<td>SOFT TISSUE (including Heart)</td>
<td>24</td>
<td>4</td>
<td>28</td>
<td>0.7</td>
</tr>
<tr>
<td>SKIN EXCLUDING BASAL &amp; SQUAMOUS</td>
<td>296</td>
<td>8</td>
<td>304</td>
<td>7.1</td>
</tr>
<tr>
<td>Melanoma—Skin</td>
<td>276</td>
<td>7</td>
<td>283</td>
<td>6.6</td>
</tr>
<tr>
<td>Other Non-EPithelial Skin</td>
<td>20</td>
<td>1</td>
<td>21</td>
<td>0.5</td>
</tr>
<tr>
<td>BREAST</td>
<td>810</td>
<td>20</td>
<td>830</td>
<td>19.5</td>
</tr>
<tr>
<td>FEMALE GENITAL SYSTEM</td>
<td>248</td>
<td>32</td>
<td>280</td>
<td>6.6</td>
</tr>
<tr>
<td>Cervix Uteri</td>
<td>17</td>
<td>0</td>
<td>17</td>
<td>0.4</td>
</tr>
<tr>
<td>Corpus &amp; Uterus, NOS</td>
<td>158</td>
<td>6</td>
<td>164</td>
<td>3.9</td>
</tr>
<tr>
<td>Ovary</td>
<td>49</td>
<td>5</td>
<td>54</td>
<td>1.3</td>
</tr>
<tr>
<td>Vagina</td>
<td>1</td>
<td>4</td>
<td>5</td>
<td>0.1</td>
</tr>
<tr>
<td>Vulva</td>
<td>8</td>
<td>15</td>
<td>23</td>
<td>0.5</td>
</tr>
<tr>
<td>Other Female Genital Organs</td>
<td>15</td>
<td>2</td>
<td>17</td>
<td>0.4</td>
</tr>
<tr>
<td>MALE GENITAL SYSTEM</td>
<td>457</td>
<td>34</td>
<td>491</td>
<td>11.5</td>
</tr>
<tr>
<td>Prostate</td>
<td>438</td>
<td>34</td>
<td>472</td>
<td>11.1</td>
</tr>
<tr>
<td>Testis</td>
<td>18</td>
<td>0</td>
<td>18</td>
<td>0.4</td>
</tr>
<tr>
<td>Penis</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0.0</td>
</tr>
<tr>
<td>URINARY SYSTEM</td>
<td>286</td>
<td>14</td>
<td>300</td>
<td>7.0</td>
</tr>
<tr>
<td>Urinary Bladder</td>
<td>164</td>
<td>12</td>
<td>176</td>
<td>4.1</td>
</tr>
<tr>
<td>Kidney &amp; Renal Pelvis</td>
<td>106</td>
<td>2</td>
<td>108</td>
<td>2.5</td>
</tr>
<tr>
<td>Ureter</td>
<td>4</td>
<td>0</td>
<td>4</td>
<td>0.1</td>
</tr>
<tr>
<td>Other Urinary Organs</td>
<td>13</td>
<td>0</td>
<td>13</td>
<td>0.3</td>
</tr>
<tr>
<td>EYE &amp; ORBIT</td>
<td>5</td>
<td>1</td>
<td>6</td>
<td>0.1</td>
</tr>
<tr>
<td>BRAIN &amp; OTHER NERVOUS SYSTEMS</td>
<td>214</td>
<td>9</td>
<td>223</td>
<td>5.2</td>
</tr>
<tr>
<td>Brain</td>
<td>43</td>
<td>3</td>
<td>46</td>
<td>1.1</td>
</tr>
<tr>
<td>Cranial Nerves &amp; Other Nervous Systems</td>
<td>171</td>
<td>6</td>
<td>177</td>
<td>4.2</td>
</tr>
<tr>
<td>ENDOCRINE SYSTEM</td>
<td>203</td>
<td>17</td>
<td>220</td>
<td>5.2</td>
</tr>
<tr>
<td>Thyroid</td>
<td>128</td>
<td>7</td>
<td>135</td>
<td>3.2</td>
</tr>
<tr>
<td>Other Endocrine including Thyroid</td>
<td>75</td>
<td>10</td>
<td>85</td>
<td>2.0</td>
</tr>
<tr>
<td>LYMPHOMA</td>
<td>168</td>
<td>11</td>
<td>179</td>
<td>4.2</td>
</tr>
<tr>
<td>Hodgkin’s Lymphoma</td>
<td>15</td>
<td>1</td>
<td>16</td>
<td>0.4</td>
</tr>
<tr>
<td>Non-Hodgkin’s Lymphoma</td>
<td>153</td>
<td>10</td>
<td>163</td>
<td>3.8</td>
</tr>
<tr>
<td>MYELOMA</td>
<td>68</td>
<td>7</td>
<td>75</td>
<td>1.8</td>
</tr>
<tr>
<td>LEUKEMIA</td>
<td>120</td>
<td>7</td>
<td>127</td>
<td>3.0</td>
</tr>
<tr>
<td>Lymphocytic Leukemia</td>
<td>64</td>
<td>3</td>
<td>67</td>
<td>1.6</td>
</tr>
<tr>
<td>Acute Lymphocytic Leukemia</td>
<td>3</td>
<td>1</td>
<td>4</td>
<td>0.1</td>
</tr>
<tr>
<td>Chronic Lymphocytic Leukemia</td>
<td>60</td>
<td>2</td>
<td>62</td>
<td>1.5</td>
</tr>
<tr>
<td>Other Lymphocytic Leukemia</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0.0</td>
</tr>
<tr>
<td>Myeloid &amp; Monocytic Leukemia</td>
<td>53</td>
<td>4</td>
<td>57</td>
<td>1.3</td>
</tr>
<tr>
<td>Acute Myeloid Leukemia</td>
<td>41</td>
<td>1</td>
<td>42</td>
<td>1.0</td>
</tr>
<tr>
<td>Chronic Myeloid Leukemia</td>
<td>12</td>
<td>3</td>
<td>15</td>
<td>0.4</td>
</tr>
<tr>
<td>Other Leukemia</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td>0.1</td>
</tr>
<tr>
<td>Other Acute Leukemia</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0.0</td>
</tr>
<tr>
<td>Acute Lymphocytic &amp; NOS</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>0.0</td>
</tr>
<tr>
<td>MESOTHELIOMA</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td>0.1</td>
</tr>
<tr>
<td>KAPOSI SARCOMA</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td>0.1</td>
</tr>
<tr>
<td>OTHER &amp; UNKNOWN SITES</td>
<td>129</td>
<td>3</td>
<td>132</td>
<td>3.1</td>
</tr>
<tr>
<td>TOTAL</td>
<td>4,059</td>
<td>199</td>
<td>4,258</td>
<td>100.0</td>
</tr>
</tbody>
</table>
Mihir Bhayani, MD
•  Member, NCI Rare Tumors Task Force
•  American Board of Otolaryngology Writers Task Force
•  AHNS Prevention and Early Detection Committee, Survivorship Committee
•  Program Committee International Federation for Head and Neck Oncology and Surgery

Editorial:
•  Manuscript Reviewer: Oral Oncology, Head and Neck, JAMA—Otolaryngology Head and Neck Surgery, Oncotarget, Otolaryngology Head and Neck Surgery

Bruce Brockstein, MD
•  Member, Head and Neck Committee, Eastern Cooperative Oncology Group, 2000-present

Editorial:
•  Manuscript Reviewer: Head and Neck, Annals of Surgical Oncology
•  Grant Reviewer: Cancer Research UK
•  UpToDate (Online Textbook), Chapter Editor, Head and Neck Cancer, 2000-present

Nicholas Campbell, MD
•  Reviewer: Clinical Lung Cancer, Case Reports

Claus Fimmel, MD, CPE
•  Advisory Board, American Liver Foundation, Chicago Chapter, 2008-present

Editorial:
•  The Open Proteomics Journal (ISSN 1875-0397) (2008-present)
•  Liver Cancer Review Letters (2009-present)

David Grinblatt, MD
•  Community Oncology Committee, Alliance for Clinical Trials in Oncology, 2010-present

Editorial:
•  Ad Hoc Reviewer: Annals of Oncology, 1996-present

Brian Helfand, MD
•  Principal Investigator, Prostate Cancer SPORE project concerning genetics underlying active surveillance failures
•  Visiting Professorships in Shanghai China
•  Member, Bladder Cancer Consortium and Guideline Committee
•  Member, Relative Value Scale Update Committee (RUC)
•  45 peer-reviewed publications this year

Thomas Hensing, MD
•  Respiratory Health Association, Lung Cancer Initiative Advisory Council, 2005-present
•  Alliance for Clinical Trials in Oncology, Respiratory Committee Member, 2010-present

Melissa Hogg, MD
•  Co-Chair of the HPB Task Force, SAGES
•  Co-Chair of the HPB Disease Site Working Group, SSO
•  Associate Editor, “Surgical Techniques” Division, Journal of Surgical Oncology
•  Chair of the Training and Implementation Committee for the International Evidence-Based Consensus Guidelines of Minimally Invasive Pancreas Resections
•  Founding Member of the International Consortium on Minimally Invasive Pancreatic Surgery

Jason Kaplan, MD
•  Member, Southwestern Oncology Group (SWOG), Committees on Lymphoma, Myeloma, and Leukemia, 2015-present

Karen Kaul, MD, PhD
•  American Board of Pathology: Appointed Trustee, 2011-present; ACGME Residency Program Review Committee, 2012-present; Secretary, Executive Committee, 2015-present; Communications Task Force, 2012-present; Chair, Test Development & Advisory Committee for Molecular Genetics, 2012-present; Vice President, Executive Committee, 2017; President, Executive Committee, 2018; ABP/PROD Entrustable Professional Activities Task Force, 2017; Maintenance of Certificate Committee, 2012-present; Credentials Committee, 2012-present; ACGME Milestones 2 Committee, 2018-present
•  College of American Pathologists, Member, Executive Advisory Board, Archives of Pathology & Laboratory Medicine, 2015-present
•  PRODS (Pathology Residency Program Directors), Member PRODS Council, 2009-present; Council of Medical Specialty Societies/OPDA representative, 2009-present; Training Residents in Genomics (TRIG) Joint Committee, 2010-present
•  Association of Pathology Chairs, Member, 2012-present; elected Chair, GME Committee, 2015-2018; Executive Council, 2015-present
•  Ad Hoc Member, NIH/NCI P01 reviewer, 2001-present
•  SBIR Review Panels, various (Panel Chairperson 2010-present), 2008-present
•  Peer Reviewer, Prostate Cancer Foundation, 2010-present
•  Peer Reviewer, University of Chicago CTSA Pilot Program, 2011-present
•  Chair, NorthShore Auxiliary Breast/Ovarian Research Program, 2013-present

Editorial Activities:
•  Editorial Board, Annual Review of Pathology, 2011-present
•  Associate Editor, Academic Pathology, 2014-present
•  Executive Advisory Board, Archives of Pathology & Laboratory Medicine, 2015-present
•  Ad Hoc Reviewer: Cell Growth and Differentiation, Pediatric Pathology, Cancer, Clinical Microbiology Reviews, Tubercle, Chest, Archives of Pathology & Laboratory Medicine, Clinical Chemistry, American Journal of Clinical Pathology, 1996-present

Janardan Khandekar, MD
Editorial:
•  Reviewer: JAMA Oncology, Journal of National Cancer Institute
•  Associate Editor, Journal of Surgical Oncology

Katherine Kopkash, MD
•  Oncoplastic Surgery Committee for the American Society of Breast Surgeons
•  Chair of Oncoplastic Breast Surgery for Beginners Curriculum Committee, American Society of Breast Surgeons
•  Chicago Surgical Society Young Surgeons Committee

Seth Krantz, MD
•  Invited Question Writer, Self-Education Self-Assessment in Thoracic Surgery (SESATS) XII (13), American Board of Thoracic Surgery

Robert Marsh, MD
•  Eastern Cooperative Oncology Group, GI Committee

Editorial Work:

Leslie Mendoza Temple
•  Guest Editor, Complementary Therapies in Medicine special issue of Medical Cannabis, for 2021 publication

Catherine Pesce, MD
•  Young Surgeons Committee of the Chicago Surgical Society

Richard Prinz, MD
•  Editorial Review Board: Surgery, Langenbeck’s Archives of Surgery

Gustavo Rodriguez, MD
•  Member, Cancer Prevention and Control Committee, Gynecologic Oncology Group/NRG, 1997-present
•  Advisory Board, Gilda’s Club, Chicago, IL, 2004-present

Carol Rosenberg, MD
•  Chair of 2018 Cancer Survivorship Symposium, ASCO-ACP-AAP Advancing Care and Research—A Primary Care and Oncology Collaboration
•  Patient-Centered Outcomes Research Initiative (PCORI) National Comparative Effectiveness Evaluation of Survivorship Programs in the United States. LIFE Site Project Supervisor—LIFE Program Participant Program
•  Research Investigator, Women’s Health Initiative study, National Institutes of Health (NIH), 1999-present

Awards:
•  Myra Rubenstein Weis LIFE Program Grant Award Recipient: Myra Rubenstein Weis Health Resource Center Foundation, NorthShore University HealthSystem, May 2019 continued >
Prem Seth, PhD
- Editorial Board, Cancer Gene Therapy
- Editorial Board, Molecular Therapy—Oncolytics

Daniel Shevrin, MD
- Director, Advocacy Core Prostate SPORE, Northwestern University, 2003-present
- Medical Director, NorthShore Chapter of US TOO Prostate Cancer Support Group, 2002-present
- Board Member, Cancer Wellness Center; Northbrook, IL, 2010-present
- Member, National Cancer Institute (NCI) GU Steering Committee, 2014-2017

Mark Sisco, MD, FACS
- Program Committee, Breast Subsection, American Society of Plastic Surgeons, 2015-present
- In-Service Examination Committee, American Society of Plastic Surgeons, 2016-present

Editorial:
- Editorial Board Member and Peer Reviewer, Microsurgery, 2017
- Peer Reviewer, Cancer Control, 2017
- Editorial Board Member and Peer Reviewer, Journal of Surgical Oncology, 2014-present
- Peer Reviewer, Journal of Surgical Research, 2010-present

Norman Smith, MD
- Member, American Urological Association Relative Value Scale Update Committee (RUC) (2016-present); Coding and Reimbursement Committee (2016-present); Public Policy Council (2015-present)
- Vice Chair, AMA/Specialty Society Relative Value Scale Update Committee (RUC), Relativity Assessment Workgroup (2019-present)

Mark Talamonti, MD
- Society of Surgical Oncology, Foundation Board of Directors, 2014-2019; Chairman, Corporate Relations Committee, 2017-2019; Chairman, Local Arrangements Committee, 2017-2018
- Western Surgical Association, Membership Committee, 2012-present; Treasurer, 2012-present; Elected President, 2017-2018
- Americas Hepato-Pancreato-Biliary Association, 2018-2020; Finance Committee, 2019-2021; AHPBA Member at Large—Executive Council

Katharine Yao, MD
- Member, Patient-Reported Outcomes Working Group, American Society of Breast Surgeons
- Member, Publications Committee, American Society of Breast Surgeons
- Member, Practice Advocacy Committee, American Society of Breast Surgeons
- Alliance for Clinical Trials, Prevention Committee, Women’s Cancer Working Group Chair
- Vice Chair, National Accreditation Program for Breast Centers
- American College of Radiology, Supersite Screening for Breast Density, Appropriateness Criteria Breast Imaging Committee
- President-Elect, Chicago Surgical Society
- Dudley P. Allen Visiting Professor at University of Chicago Hospitals Cleveland Medical Center, September 25, 2019

Grant Awards:
- Invited speaker: Dutch Breast Cancer Conference, Bossche Mammo Congress, June 18-19, 2019
- 2019 Special Guest Speaker at the PANCan PurpleStride, June 29, 2019 @ Soldier Field

Locations

Chicago Lake Shore Medical Office (CH)
680 North Lake Shore Drive, Suite 924
Chicago, IL 60611

Evanston Breast Center (EVB)
2650 Ridge Avenue, Evanston, IL 60201

Evanston Hospital (EH)
2650 Ridge Avenue, Evanston, IL 60201

Evanston Kellogg Cancer Center (EVK)
2650 Ridge Avenue, Evanston, IL 60201

Evanston Specialty Suites (EV)
1000 Central Street, Evanston, IL 60201

Glenbrook Breast Center (GBB)
2050 Pfingsten Road, Suite 130
Glennview, IL 60026

Glenbrook Hospital (GBH)
2180 Pfingsten Road, Glenview, IL 60026

Glenbrook John and Carol Walter Ambulatory Care Center (GB)
2180 Pfingsten Road, Suite 100
Glennview, IL 60026

Glenbrook Medical Building (GBM)
2050 Pfingsten Road, Suite 128
Glennview, IL 60026

Glenview Park Center (GP)
2400 Chestnut Avenue, Glenview, IL 60026

Gurnee Ambulatory Care Center (GR)
7902 Rollins Road, Gurnee, IL 60031

Highland Park Ambulatory Care Center (HPS)
757 Park Avenue West, Highland Park, IL 60035

Highland Park Breast Center (HPB)
777 Park Avenue West, Suite B400
Highland Park, IL 60035

Highland Park Hospital (HPH)
777 Park Avenue West, Room 1260
Highland Park, IL 60035

Highland Park Kellogg Cancer Center (HPK)—Ellen Marks Ambulatory Care Center
757 Park Avenue West, Suite 1810
Highland Park, IL 60035

Highland Park Medical Building (HP)
767 Park Avenue West, Suite B100
Highland Park, IL 60035

Lake Bluff Medical Building (LB)
71 Waukegan Road, Suite 700
Lake Bluff, IL 60044

Mount Prospect Medical Building (MP)
1329 Wolf Road, Mount Prospect, IL 60056

Northbrook Medical Building (NMB)
501 Skokie Boulevard, Northbrook, IL 60062

NorthShore Medical Group (SKM)—Skokie
9933 Woods Drive, Suite 200, Skokie, IL 60077

Skokie Ambulatory Care Center (SK)
9650 Gross Point Road, Suite 3000
Skokie, IL 60077

Vernon Hills Specialty Suites (VH)
225 North Milwaukee Avenue
Vernon Hills, IL 60061
Physician Directory
Physician Directory

Monika Krezalek, MD
Expertise: Minimally Invasive Colon and Rectal Surgery; Colon and Rectal Cancer; Inflammatory Bowel Disease; Anorectal Surgery; Colonoscopy
Locations: EV, HPS, GR

Teresa Murray Law, MD
Expertise: Breast Cancer; Prostate Cancer; Genitourinary Cancer
Locations: EVK, GR, HPK

Ross Levy, MD
Expertise: Mohs Surgery; Dermatologic Surgery; Laser Surgery
Location: SKM

John Linn, MD
Vice Chair for Surgery, Glenbrook Hospital
Expertise: Gastrointestinal Surgical Oncology Including Stomach and Esophagus; Weight Loss Surgery; General Surgery
Locations: EV, GBM

Luzheng Liu, MD
Expertise: General Dermatology; Skin Cancers
Location: LB

Konanahalli Madhuri, MD
Expertise: Skin Cancer; General Dermatology
Location: EV

Robert Marsh, MD
Section Chief, GI Oncology
Expertise: GI Oncology
Locations: EVK, GBK

Andrew Melnyk, MD
Expertise: Medical Genetics
Locations: EV, GBM

Gregg Menaker, MD
Expertise: Mohs Surgery; Dermatologic Surgery; Laser Surgery
Location: SKM

Douglas Merkel, MD
Expertise: Breast Cancer
Locations: EVK, GBK, HPK

Ryan Merrell, MD
Program Director; Neuro-Oncology; Expertise: Brain Cancer; Brain Tumor; Neurologic Complications of Cancer; Tumor in the Central Nervous System (Brain or Spine)
Locations: EVK, GB, GBK

Tricia Moo-Young, MD
Expertise: Minimally Invasive Approaches to Endocrine Disorders; Thyroid and Parathyroid Surgery; Adrenal Disorders; Pancreatic Exocrine; General Surgery
Locations: HPS, VH

Elena Moore, MD
Expertise: Cervical Cancer; Endometrial Cancer; Fallopian Tube Cancer; Ovarian Cancer; Uterine Cancer; Vaginal Cancer; Vulvar Cancer
Locations: EVK, HPK

Joseph Muldoon, MD
Expertise: Minimally Invasive Colon and Rectal Surgery; Colon and Rectal Cancer; Inflammatory Bowel Disease; General Surgery
Locations: EV, GBK, GBM

Ranjeev Nanda, MD
Expertise: Stereotactic Radiosurgery; Brain Tumors; Head and Neck Cancers
Locations: EH, GBH

Cheryl Nocon, MD
Expertise: Head and Neck Cancers; Thyroid and Parathyroid Surgery; Microvascular Reconstruction
Locations: EVK, SK, VH

Kristian Novakovic, MD
Expertise: Kidney Cancer; Prostate Cancer
Locations: EV, GB

Bernhard Ortel, MD
Division Head, Dermatology
Expertise: Skin Cancer; General Dermatology; Psoriasis; Blistering Diseases
Location: SKM

Joseph Raviv, MD
Expertise: Endoscopic Sinus and Anterior Skull Base Surgery
Locations: EV, NMB

Erwin Robin, MD
Expertise: Benign and Malignant Hematology
Locations: GB, HP, SK

Gustavo Rodriguez, MD
Division Head, Gynecologic Oncology
Expertise: Gynecologic Oncology
Location: EVK

For more information, visit northshore.org/cancer or call (847) 570-2112
For more information, visit northshore.org/cancer or call (847) 570-2112

<table>
<thead>
<tr>
<th>Name</th>
<th>Expertise</th>
<th>Locations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carol Rosenberg, MD</td>
<td>Director, Preventive Health Initiatives;</td>
<td>EVB, EVK, HPK, LB</td>
</tr>
<tr>
<td></td>
<td>Director, Myra Rubenstein Weiss Living in the Future (LIF) Cancer Survivorship Program</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Expertise: Cancer Survivorship</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Location: HPH</td>
<td></td>
</tr>
<tr>
<td>Poornima Saha, MD</td>
<td>Expertise: Breast Cancer</td>
<td>EVK, HPK, LB</td>
</tr>
<tr>
<td></td>
<td>Location: EVK</td>
<td></td>
</tr>
<tr>
<td>Akhil Seth, MD</td>
<td>Expertise: Breast Reconstruction; Aesthetic</td>
<td>NMB</td>
</tr>
<tr>
<td></td>
<td>Breast and Body Surgery; Oncologic and Complex</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Wound Reconstruction</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Location: NMB</td>
<td></td>
</tr>
<tr>
<td>Arif Shaikh, MD</td>
<td>Expertise: Stereotactic Radiosurgery; Head</td>
<td>EH, GBH</td>
</tr>
<tr>
<td></td>
<td>and Neck Cancers; Lung Cancer; Gynecologic and</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Breast Tumors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Locations: EH, GH</td>
<td></td>
</tr>
<tr>
<td>Daniel Shevrin, MD</td>
<td>Medical Director, Glenbrook Kellogg Cancer</td>
<td>EVK, GBK</td>
</tr>
<tr>
<td></td>
<td>Center</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Expertise: Prostate Cancer; Genitourinary</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Locations: EVK, GPK</td>
<td></td>
</tr>
<tr>
<td>Michael Shinners, MD</td>
<td>Expertise: Otolaryngology/Neurotology; Lateral</td>
<td>EV, NMB</td>
</tr>
<tr>
<td></td>
<td>Skull Base Surgery</td>
<td></td>
</tr>
<tr>
<td>Mark Sisco, MD</td>
<td>Division Head, Plastic and Reconstructive</td>
<td>NMB</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Expertise: Plastic Surgery; Breast Reconstruction</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Location: NMB</td>
<td></td>
</tr>
<tr>
<td>Norm Smith, MD</td>
<td>Expertise: Bladder Cancer, Testicular Cancer,</td>
<td>EV, GB</td>
</tr>
<tr>
<td></td>
<td>Kidney Cancer, Advanced Urologic Cancers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Locations: EV, GB</td>
<td></td>
</tr>
<tr>
<td>James Spitz, MD</td>
<td>Expertise: Colon and Rectal Surgery; Colonoscopy;</td>
<td>GBM, SK, VH</td>
</tr>
<tr>
<td></td>
<td>General Surgery</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Locations: GBM, SK, VH</td>
<td></td>
</tr>
<tr>
<td>Mark Talamonti, MD</td>
<td>Department Chair, Surgery</td>
<td>EVK</td>
</tr>
<tr>
<td></td>
<td>Expertise: Gastrointestinal Surgical Oncology;</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pancreatic Cancer; Benign and Malignant Liver</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tumors; Neuroendocrine Tumors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Location: EVK</td>
<td></td>
</tr>
<tr>
<td>Leslie Mendoza Temple, MD</td>
<td>Integrative Medicine Medical Director</td>
<td>GP</td>
</tr>
<tr>
<td></td>
<td>Expertise: Integrative Medicine</td>
<td></td>
</tr>
<tr>
<td>Michael Ujiki, MD</td>
<td>Division Head, Gastrointestinal &amp; General</td>
<td>EV,GBM</td>
</tr>
<tr>
<td></td>
<td>Surgery</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Expertise: Gastrointestinal Surgical Oncology</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Including Stomach and Esophagus; Minimally</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Invasive Endoscopic Surgery; Weight Loss</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Surgery; General Surgery</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Locations: EV, GBM</td>
<td></td>
</tr>
<tr>
<td>Elaine Lee Wade, MD</td>
<td>Expertise: Breast Cancer; Benign Hematology</td>
<td>GBK</td>
</tr>
<tr>
<td>Jason Waldinger, MD</td>
<td>Expertise: Skin Cancer; General Dermatology;</td>
<td>LB</td>
</tr>
<tr>
<td></td>
<td>Laser Procedures</td>
<td></td>
</tr>
<tr>
<td>Lauren Wiebe, MD</td>
<td>Expertise: Palliative Medicine; GI Oncology</td>
<td>EH, GB</td>
</tr>
<tr>
<td>David J. Winchester, MD</td>
<td>Associate Director for Surgical Specialties,</td>
<td>EV, GB, GBB, GBM</td>
</tr>
<tr>
<td></td>
<td>Kellogg Cancer Center</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Expertise: Surgical Oncology with Emphasis on</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Breast, Endocrine, Melanoma and Sarcoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Locations: EV, GBB, GBM</td>
<td></td>
</tr>
<tr>
<td>Ricky Wong, MD</td>
<td>Expertise: Brain, Skull and Pituitary Tumors</td>
<td>EV, GB</td>
</tr>
<tr>
<td>Katharine Yao, MD</td>
<td>Division Head, Surgical Oncology; General</td>
<td>EVB, EVK</td>
</tr>
<tr>
<td></td>
<td>Health; Breast Disease and Surgery</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Locations: GBM, SK, VH</td>
<td></td>
</tr>
</tbody>
</table>

Cancer Conferences

Breast Cancer Conferences
NorthShore Evanston Hospital
Kellogg Room G868, Mondays, 7:30 a.m.
NorthShore Glenbrook and Highland Park Hospitals Videocast

Colorectal Cancer Conferences
NorthShore Evanston Hospital
Kellogg Room G868
2nd and 4th Fridays, 7 a.m.
NorthShore Glenbrook and Highland Park Hospitals Videocast

Genitourinary Cancer Conferences
NorthShore Evanston Hospital
Kellogg Room G868
1st and 3rd Fridays, 7 a.m.
NorthShore Glenbrook Hospital Videocast

Gynecology Cancer Conferences
NorthShore Evanston Hospital
Kellogg Room G868
Thursdays, 7 a.m.
NorthShore Glenbrook and Highland Park Hospitals Videocast

Head and Neck Cancer Conferences
NorthShore Evanston Hospital
Kellogg Room G868
1st and 3rd Thursdays, 8 a.m.

Hematology/Pathology Conferences
NorthShore Evanston Hospital
Kellogg Room G868
Tuesdays, 8:00 a.m.
NorthShore Glenbrook and Highland Park Hospitals Videocast

Hepatic Biliary Pancreatic Cancer Conferences
NorthShore Evanston Hospital
Kellogg Room G868
Tuesdays, 7 a.m.
NorthShore Glenbrook and Highland Park Hospitals Videocast

Molecular Oncology Conferences
NorthShore Evanston Hospital
Kellogg Room 4818, 1st Friday, 7 a.m.

Neuro-Oncology Cancer Conferences
NorthShore Evanston Hospital
Kellogg Room G868
2nd and 4th Wednesdays, 7:30 a.m.
NorthShore Glenbrook and Highland Park Hospitals Videocast

Sarcoma/Melanoma Conferences
NorthShore Evanston Hospital
Kellogg Room G868
1st and 3rd Wednesdays, 8 a.m.
NorthShore Glenbrook and Highland Park Hospitals Videocast

Thoracic Cancer Conferences
NorthShore Evanston Hospital
Kellogg Room G868, Tuesdays, noon
NorthShore Glenbrook and Highland Park Hospitals Videocast
Chairman
David J. Winchester, MD, FACS
Associate Director for Surgical Specialties, Kellogg Cancer Center, NorthShore Cancer Committee Chairman, Board of Directors, David P. Winchester, MD, Chair of Surgical Oncology

Vice Chairman
Bruce Brockstein, MD
Medical Director, Kellogg Cancer Center, Head, Division of Hematology/Oncology, Kellogg-Scanlon Chair of Oncology, NorthShore Cancer Committee Vice-Chairman, NorthShore Cancer Committee Cancer Conference Coordinator

Physician Membership*
Matthew Adess, MD
Medical Director, Highland Park Kellogg Cancer Center

Kristina Drabkin, DO
Physical Medicine & Rehabilitation

David Grinblatt, MD
Director, Oncology Research Program Kellogg Cancer Center

Thomas Hensing, MD
Co-Director, Thoracic Oncology Program Head of Quality, Kellogg Cancer Center Deputy Division Head, Division of Hematology and Oncology Medical Director, Evanston Kellogg Cancer Center NorthShore Cancer Committee Quality Improvement Coordinator

Seth Krantz, MD
Thoracic Oncology NorthShore Cancer Committee Cancer Liaison Physician

Elena Moore, MD
Gynecologic Oncology

Kristian Novakovic, MD
Urologic Oncology

Catherine Pesce, MD
Surgical Oncology

Vathsala Raghavan, MD
Radiation Oncology

Carol Rosenberg, MD
Director, Myra Rubenstein Weis Living in the Future (LIFE) Cancer Survivorship Program

Poomima Saha, MD
Medical Oncology

Arif Shaikh, MD
Radiation Oncology

Lauren Wiebe, MD
Palliative Care

Ancillary Membership
Jonella Black, PT, MS
Program Coordinator, Rehab Services

George Carro, RPH, MS, BCOP
Senior Director, Oncology Pharmacy

Kim Cholewa, BSN
Oncology Nursing

Jamie Feld, RN
Cancer Committee Coordinator Cancer Registry

Amy Ferguson
Assistant Vice-President, Integrated Marketing and Corporate Communications

Bruce Brockstein, MD
Medical Director, Kellogg Cancer Center, Head, Division of Hematology/Oncology, Kellogg-Scanlon Chair of Oncology, NorthShore Cancer Committee Vice-Chairman, NorthShore Cancer Committee Cancer Conference Coordinator

Addie Gorchow, MBA, RHIT, CTR
Cancer Registry Abstractor II Kellogg Cancer Center

Anisha Patel, APN
Clinical Coordinator Living in the Future (LIFE) Cancer Survivorship Program

Shayna Purcell, MSGC
Medical Genetics

Denise Rehberger, RN, BSN
Manager, Hospice

Kelly Timnes
Health Systems Manager American Cancer Society

Roslyn Turner, LSW
Oncology Social Worker Kellogg Cancer Center NorthShore Cancer Committee Psychosocial Services Coordinator

Maria Velez
Coordinator, IRB Research Oncology Research NorthShore Cancer Committee Clinical Research Coordinator

Debra Ziegler, MLIS, CTR
Quality Coordinator, Cancer Registry NorthShore Cancer Committee Cancer Registry Quality Coordinator

Lisa Zoberman, RDN, LDN
Oncology Nutrition Kellogg Cancer Center

* All academic affiliations are with the University of Chicago Pritzker School of Medicine